+1-206-701-6702
+44-020-8133-4027
+050-5539-1737
+91-848-285-0837
Press Release: Typhoid Fever Vaccines Market to Surpass US$ 554.4 Mn Threshold by 2026
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Typhoid Fever Vaccines Market- Insights
Typhoid fever, also simply called as typhoid is a bacterial infection caused by Salmonella typhi, also known as Salmonella enterica serotype Typhi. The typhoid fever is usually caused due to ingestion of contaminated food or water. Typhoid vaccines prevents typhoid fever and provide protection against it. World Health Organization (WHO) has recommended three typhoid vaccines for use, which include live attenuated vaccine, capsular polysaccharide vaccines, and conjugate vaccine
Increasing government initiatives promoting and advancing development of innovative products
Organizations such as World Health Organization (WHO), Gavi, Bill & Melinda Gates Foundation, and others are highly active in creating awareness regarding typhoid and driving immunization efforts against such diseases
For instance, in October 2017, WHO recommended introduction of typhoid vaccine for children over six months in endemic countries. It also recommended catch-up vaccination whenever possible, prioritizing children and adolescents up to 15 years of age.
Moreover, World Health Organization (WHO), pre-qualified a typhoid conjugate vaccine (TCV) Typbar TCV, manufactured by Bharat Biotech in December 2017. WHO pre-qualification enables the procurement and supply of this vaccine to UNICEF, the Pan-American Health Organization (PAHO), and GAVI (a vaccine alliance) supported countries. Such frequent initiatives taken by various organizations is expected to support the market growth over the forecast period.
High prevalence of typhoid in various emerging economies is expected to rise the demand for typhoid vaccines in near future and fuel global typhoid fever vaccines market growth. For instance, according to the International Health Metrics and Evaluation (IHME) estimates in 2016, around 12 million cases of typhoid fever were reported resulting in around 130,000 deaths globally
The global typhoid fever vaccines market size was valued at US$ 225.0 Mn in 2018, and is expected to witness a CAGR of 11.9% during the forecast period (2018 – 2026).
Figure 1. Global Typhoid Fever Vaccines Market Share (%), By Vaccine Type, 2018-2016
Source: Coherent Market Insights Analysis (2018)
Asia Pacific is expected to hold dominant position in the market owing to high prevalence of typhoid fever in the region
Asia Pacific is expected to be most lucrative region for typhoid fever vaccines market growth, owing to countries such as India, Pakistan, and Bangladesh are endemic to typhoid wherein the demand for typhoid vaccine is every high. For instance, according to the data published by Med India around 18, 45,997 cases of typhoid were found in India in 2015. Furthermore, presence of key typhoid vaccine manufacturers in region and development and launch of novel vaccines by them is also expected to drastically drive market growth over the forecast period
For instance, Bharat Biotech and Bio-Med Private Limited are two India-based typhoid vaccine manufacturer in Asia Pacific. In 2013, Bharat Biotech launched its new clinically proven conjugate Typhoid vaccine namely Typbar-TCV, which offers long-term protection and can be given to children as young as six months.
Figure 2. Global Typhoid Fever Vaccines Market Share (%) Analysis, By Region, 2026
Source: Coherent Market Insights Analysis (2018)
Reimbursement Scenario
Vaccination/Immunizations are generally not covered under medicare, unless they are directly related to the treatment of an injury or direct exposure to a disease or condition, such as anti-rabies treatment or tetanus antitoxin or booster vaccine.
In absence of such condition where an injury or direct exposure has happened, vaccination (preventive immunization) against diseases such as smallpox, typhoid and polio, are not covered.
In cases where a vaccination or inoculation is excluded from coverage, the entire charge will be denied (such as office visits, which are primarily for the purpose of administering a non-covered injection).
Market Opportunity
Currently, there is only one typhoid conjugate vaccine that has been prequalified by WHO (Typbar TCV) to treat young children below two years of age. Typhoid conjugate vaccine (TCV) is more effective at preventing the disease than other available vaccines. It is long lasting, provides protection for at least five years and possibly longer, as compared to just two years for earlier typhoid vaccines.
Childhood vaccination schedules are still devoid of a typhoid vaccine. However, with introduction of Typbar TCV, the scenario is expected to change, as these vaccines would be included in the childhood vaccination schedules giving immunity against typhoid to infants early.
Typhoid conjugate vaccine increased the immunization age range to include children under age two, a particularly vulnerable and typhoid susceptible part of the population. Manufacturers can develop novel typhoid vaccine with better and longer clinical protection, broader target age range (including children <2 years of age), cost effectiveness, and other factors, which are not met by currently available vaccines
Key players operating in the typhoid fever vaccines market include GlaxoSmithKline Plc., Sanofi SA, Bharat Biotech, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax, Inc. Shanghai Institute of Biological Products Co., Ltd., and Prokarium
Typhoid fever is a bacterial infection caused by Salmonella typhi, which causes symptoms such as prolonged fever, headache, nausea, loss of appetite, and constipation or sometimes diarrhea. Typhoid fever is majorly caused in area with poor sanitation and lack of clean drinking water. Typhoid fever vaccines are the biological formulation, which provide immunity and protects an individual against typhoid fever
Currently there are three typhoid vaccines recommended World Health organization (WHO) for use which include:
Market Dynamics
High prevalence of typhoid fever in region such as Asia Pacific and Africa is expected to drastically rise demand for its vaccines and support global typhoid fever vaccines market growth over the forecast period.
For instance, according to the data published by World Health Organization (WHO) in September 2018, globally between 11 and 21 million cases of typhoid were found, which caused around 128 000 to 161 000 typhoid-related deaths occur annually.
According to the data published by National Center for Biotechnology Information (NCBI) in 2018, incidence of typhoid fever in Africa was estimated to be 10–100 cases per 100,000
Increasing initiatives by government and various other organizations to increase awareness about typhoid vaccine and rising access of new vaccines is expected to support typhoid fever vaccines market growth during forecast period.
For instance, in February 2019, Gavi, the Vaccine Alliance in partnership with WHO, CDC and Zimbabwe’s Ministry of Health launched a campaign to tackle typhoid outbreak in Zimbabwe. The campaign aims to vaccinate 325,000 people in nine suburbs of Zimbabwe’s capital with new typhoid conjugate vaccine (TCV).
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 26 market data tables and 325 figures on “Typhoid Fever Vaccines Market - Global forecast to 2026”.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Contact Us
